Bristol-Myers fourth quarter below analysts estimates – The Pharma Letter
The Star-Ledger – NJ.comBristol-Myers fourth quarter below analysts estimatesThe Pharma LetterThis concludes a year in which the company received important new product approvals for Yervoy (ipilimumab) for the treatment of metastatic melanoma and kidne…